Literature DB >> 31710572

APOL1 and Kidney Disease: From Genetics to Biology.

David J Friedman1, Martin R Pollak1.   

Abstract

Genetic variants in the APOL1 gene, found only in individuals of recent African ancestry, greatly increase risk of multiple types of kidney disease. These APOL1 kidney risk alleles are a rare example of genetic variants that are common but also have a powerful effect on disease susceptibility. These alleles rose to high frequency in sub-Saharan Africa because they conferred protection against pathogenic trypanosomes that cause African sleeping sickness. We consider the genetic evidence supporting the association between APOL1 and kidney disease across the range of clinical phenotypes in the APOL1 nephropathy spectrum. We then explore the origins of the APOL1 risk variants and evolutionary struggle between humans and trypanosomes at both the molecular and population genetic level. Finally, we survey the rapidly growing literature investigating APOL1 biology as elucidated from experiments in cell-based systems, cell-free systems, mouse and lower organism models of disease, and through illuminating natural experiments in humans.

Entities:  

Keywords:  APOL1; FSGS; HIV-associated nephropathy; HIVAN; Trypanosoma; focal segmental glomerulosclerosis; genetic variant; hypertensive kidney disease

Year:  2019        PMID: 31710572     DOI: 10.1146/annurev-physiol-021119-034345

Source DB:  PubMed          Journal:  Annu Rev Physiol        ISSN: 0066-4278            Impact factor:   19.318


  31 in total

1.  The Mechanism of Kidney Disease Due to APOL1 Risk Variants.

Authors:  Etienne Pays
Journal:  J Am Soc Nephrol       Date:  2020-09-17       Impact factor: 10.121

2.  Pulling the Hood off Genetic Susceptibility to Hypertensive Renal Disease.

Authors:  Isha S Dhande; Peter A Doris
Journal:  J Am Soc Nephrol       Date:  2020-03-02       Impact factor: 10.121

3.  GWAS in Mice Maps Susceptibility to HIV-Associated Nephropathy to the Ssbp2 Locus.

Authors:  Nicholas J Steers; Yask Gupta; Vivette D D'Agati; Tze Y Lim; Natalia DeMaria; Anna Mo; Judy Liang; Kelsey O Stevens; Dina F Ahram; Wan Yee Lam; Mihai Gagea; Lalitha Nagarajan; Simone Sanna-Cherchi; Ali G Gharavi
Journal:  J Am Soc Nephrol       Date:  2021-12-10       Impact factor: 10.121

4.  High Density Lipoproteins: Is There a Comeback as a Therapeutic Target?

Authors:  Arnold von Eckardstein
Journal:  Handb Exp Pharmacol       Date:  2022

5.  Cation Channel Activity of Apolipoprotein L1 is Modulated by Haplotype Background.

Authors:  Rebecca L Winkler; Jonathan Bruno; Paula Buchanan; John C Edwards
Journal:  J Am Soc Nephrol       Date:  2022-07-15       Impact factor: 14.978

Review 6.  APOL1 Nephropathy: From Genetics to Clinical Applications.

Authors:  David J Friedman; Martin R Pollak
Journal:  Clin J Am Soc Nephrol       Date:  2020-07-02       Impact factor: 8.237

Review 7.  Extrapulmonary manifestations of COVID-19.

Authors:  Aakriti Gupta; Mahesh V Madhavan; Kartik Sehgal; Nandini Nair; Shiwani Mahajan; Tejasav S Sehrawat; Behnood Bikdeli; Neha Ahluwalia; John C Ausiello; Elaine Y Wan; Daniel E Freedberg; Ajay J Kirtane; Sahil A Parikh; Mathew S Maurer; Anna S Nordvig; Domenico Accili; Joan M Bathon; Sumit Mohan; Kenneth A Bauer; Martin B Leon; Harlan M Krumholz; Nir Uriel; Mandeep R Mehra; Mitchell S V Elkind; Gregg W Stone; Allan Schwartz; David D Ho; John P Bilezikian; Donald W Landry
Journal:  Nat Med       Date:  2020-07-10       Impact factor: 53.440

Review 8.  Apolipoprotein L1 and mechanisms of kidney disease susceptibility.

Authors:  Leslie A Bruggeman; John R Sedor; John F O'Toole
Journal:  Curr Opin Nephrol Hypertens       Date:  2021-05-01       Impact factor: 2.894

Review 9.  Kidney disease and APOL1.

Authors:  Aminu Abba Yusuf; Melanie A Govender; Jean-Tristan Brandenburg; Cheryl A Winkler
Journal:  Hum Mol Genet       Date:  2021-04-26       Impact factor: 6.150

10.  COVID-19 and APOL1: Understanding Disease Mechanisms through Clinical Observation.

Authors:  David J Friedman
Journal:  J Am Soc Nephrol       Date:  2020-12-07       Impact factor: 10.121

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.